Publications & Presentations

BVD Authored

Cancer Research Communications, May 2024

A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma

View abstract

Nature Communications, March 2024

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

View abstract

RAS-TARGETED DRUG DEVELOPMENT SUMMIT, SEPTEMBER 2023

Ulixertinib, a first-in-class ERK1/2 inhibitor, as an effective combination agent in RAS mutated malignancies

View poster

ASCO ANNUAL MEETING, JUNE 2023

A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ)

View poster

AACR ANNUAL MEETING, APRIL 2023

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors

View poster

AACR ANNUAL MEETING, APRIL 2023

Combining ulixertinib (ERK1/2 inhibitor) with EGFR and BRAF inhibition yields significant efficacy in preclinical BRAFV600E mutant colorectal cancer models

View poster

AACR Annual Meeting, APRIL 2023

The combination of ulixertinib (ERK1/2 inhibitor) and KRASG12C inhibition demonstrates significant efficacy in preclinical models

View poster

Neuro-Oncology, March 2023 (print); July 2022 (online)

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models

View abstract

Melanoma Research, August 2022 (print); May 2022 (online)

Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma

View abstract

AACR Annual Meeting, April 2022

ERK1/2 inhibitor ulixertinib demonstrates activity in atypical (non-V600) BRAF mutant models

View abstract View poster

AACR ANNUAL MEETING, APRIL 2022

Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered models

View abstract View poster

AACR ANNUAL MEETING, APRIL 2022

The characterization of in vitro models demonstrating a significant delay of acquired resistance to ulixertinib (ERK1/2)

View abstract View poster

AACR ANNUAL MEETING, APRIL 2022

Identification of combination partners to combat acquired resistance to ulixertinib (ERK1/2 inhibitor) using transcriptomics

View abstract View poster

Radiation Research, March 2022 (print); December 2021 (online)

Paired 18F-Fluorodeoxyglucose (18F-FDG), and 64Cu-Copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (64Cu-ATSM) PET scans in dogs with spontaneous tumors and evaluation for hypoxia-directed therapy

View abstract

Nature / Biopharma Dealmakers, September 2021

Translational medicine: doing things differently

View PDF

Investigational New Drugs, June 2021 (print); January 2021 (online)

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

View abstract

Clinical Cancer Research, January 2021 (print); October 2020 (online)

Intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors

View abstract

Journal for ImmunoTherapy for Cancer, August 2018

White paper on microbial anti-cancer therapy and prevention

View abstract

The Journal of Clinical Investigation, June 2018 (online); July 2018 (print)

Tumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release

View abstract

Cancer Discovery, September 2018 (print); June 2018 (online)

Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine

View abstract

BMC Veterinary Research, April 2018

Identification of immunologic and clinical characteristics that predict inflammatory response to C. novyi-NT bacteriolytic immunotherapy

View abstract

Veterinary Research, April 2018

Immune response to Clostridium novyi-NT immunotherapy

View abstract

Veterinary Research, April 2018

Translational and Clinical Development of Clostridium novyi-NT

View abstract

Cancer Chemotherapy and Pharmacology, June 2018 (print), March 2018 (online)

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies

View abstract

Cancer Discovery, February 2018 (print); December 2017 (online)

First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a Phase I dose-escalation and expansion study

View abstract Read first author interview

Joint Meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research, October 18 – 21, 2017

Activity of the ERK1/2 inhibitor ulixertinib in patients with BRAF and NRAS mutant melanoma

View abstract

Molecular Cancer Therapeutics, November 2017 (print); September 2017 (online)

Targeting the MAPK signaling pathway in cancer: promising preclinical activity with the novel selective ERK1/2 inhibitor BVD-523 (ulixertinib)

View abstract

National Cancer Institute (NCI) Conference on Microbial-Based Cancer Therapy, July 11-12, 2017

Clostridium novyi-NT: Transitional and Clinical Development

View meeting details View abstract

American Society of Clinical Oncology (ASCO), June 2017

A first-in-class Phase 1 dose-escalation study of the novel oral ERK1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors

View abstract View presentation View press release

Cancer Cell, April 2017

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature

View abstract Read commentary

American Association for Cancer Research (AACR), April 2017

Activity of ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma

View abstract

EORTC-NCI-AACR Symposium, November 29 – December 6, 2016

Phase 1 clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer

View abstract

Nuclear Medicine and Biology, May 2016 (print); February 2016 (online)

Human dosimetry and infection imaging in patients with suspected prosthetic joint infection

View abstract

American Society of Clinical Oncology (ASCO), June 2015

Dose escalation stage of a first-in-class Phase 1 study of the novel oral ERK1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors

View abstract View presentation View related video

American Association for Cancer Research (AACR), April 2015

The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance

View abstract View presentation

13th International Congress on Targeted Anticancer, March 2015

Phase 1 clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer

View abstract View poster

Symposium on Clinical Interventional Oncology (CIO), January 2015

Phase 1 trial of image-guided oncolysis by Clostridium novyi-NT spore inoculation: early technical insights

View abstract

PLoS One, Dec 2014

MRI-monitored intra-tumoral injection of iron-oxide labeled Clostridium novyi-NT anaerobes in pancreatic carcinoma mouse model

View abstract

Science Translational Medicine, August 2014

Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses

View abstract

World Journal of Microbiology and Biotechnology, August 2014

Evaluation of 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent

View abstract

PLoS One, Aug 2014

Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity

View abstract

Current Therapeutic Research, December 2013

Possible therapeutic effect of trilostane in rodent models of inflammation and nociception

View abstract

Pharmacology, November 2013

Novel anti-inflammatory effects of doxazosin in rodent models of inflammation

View abstract

BMC Nephrology, October 2013

TNF-α blockade is ineffective in animal models of established polycystic kidney disease

View abstract

Current Therapeutic Research, September 2012

Differential effects of cyclosporin and etanercept treatment on various pathologic parameters in a murine model of irradiation-induced mucositis

View abstract

Current Therapeutic Research, December 2011

In vivo effects of immunomodulators in a murine model of Fluorouracil-induced mucositis

View abstract

Pharmacology, November 2011

Novel anti-inflammatory effects of repaglinide in rodent models of inflammation

View abstract

Diabetes, Obesity and Metabolism, November 2011

Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion

View abstract

Pharmacology, August 2011

Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models

View abstract

Supporting Literature

New Scientist, June 2023

Bugging cancer

View PDF

Journal for ImmunoTherapy of Cancer, September 2022

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity

View abstract

Biochemical Journal, April 2023

ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1

View abstract

Nature Communications, 2022

Cancer cell survival depends on collagen uptake into tumor-associated stroma

View abstract

Cancers, 2022

ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo

View abstract

Nature Communications, 2021

TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer

View abstract

Cancer Management and Research, 2021

Clinical Value of Detecting Tumor Endothelial Marker 8 (ANTXR1) as a Biomarker in the Diagnosis and Prognosis of Colorectal Cancer

View abstract

The Journal of Clinical Investigation, July 2018

Deadly DAaRTS destroy cancer cells via a tumor microenvironment–mediated trigger

View abstract

Cancer Research, 2018

TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer

View abstract